Author(s) Details:
Khaled Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Roberto De Giorgio
Department of Translational Sciences, University of Ferrara, Ferrara, Italy.
Rami Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
This section is a part of the chapter: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review
Irritable bowel syndrome (IBS) is a complex disorder of gut-brain interaction (DGBI). It affects a diverse population across various age groups and ethnicities. IBS is a common medical disorder worldwide, with reported prevalence rates ranging from 5% to 35%. Patients diagnosed with IBS often experience significant disruptions in their daily activities and a diminished quality of life, which can be attributed to the limited effectiveness of conventional treatment options. Additionally, the long-term consequences of the condition may give rise to psychological challenges, potentially resulting in polypharmacy or the concurrent use of multiple medications.
How to Cite
Jadallah, K., Giorgio, R. D., & Jadallah, R. (2025). Pharmacological Advancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review. Medical Science: Trends and Innovations Vol. 4, 49–85. https://doi.org/10.9734/bpi/msti/v4/4177